Literature DB >> 31604536

CTLA-4 (CD152): A versatile receptor for immune-based therapy.

Holger Lingel1, Monika C Brunner-Weinzierl2.   

Abstract

Coreceptor-based immunotherapy is a rapidly developing approach to treat cancer patients. Among those targeted receptors, CTLA-4 is the primary attenuator of adaptive immune responses and the most prominent and extensively investigated molecule in this field. CTLA-4 is involved in broad range of mechanisms that regulate and control immune cell functions and therefore provides versatile strategies for therapeutic interventions. Despite being successfully harnessed in clinical treatments the different facets of CTLA-4 biology still remain incompletely understood. Here, we review the various aspects of CTLA-4 functions and CTLA-4-based immunotherapies and discuss challenges to improve current approaches.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Abatacept; CTLA-4; Cancer immunotherapy; Immune checkpoint; Ipilimumab

Mesh：

Substances：

Year:  2019        PMID： 31604536     DOI： 10.1016/j.smim.2019.101298

Source DB:  PubMed          Journal:  Semin Immunol        ISSN： 1044-5323            Impact factor:   11.130


  8 in total

Review 1.  The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines).

Authors:  Andrea De Giglio; Alessandro Di Federico; Giacomo Nuvola; Chiara Deiana; Francesco Gelsomino
Journal:  Curr Oncol Rep       Date:  2021-08-27       Impact factor: 5.075

Review 2.  Novel Combination Therapies for the Treatment of Bladder Cancer.

Authors:  Mei Peng; Di Xiao; Yizhi Bu; Jiahui Long; Xue Yang; Shuhe Lv; Xiaoping Yang
Journal:  Front Oncol       Date:  2021-01-27       Impact factor: 6.244

Review 3.  Targeting Host Cellular Factors as a Strategy of Therapeutic Intervention for Herpesvirus Infections.

Authors:  Kumari Asha; Neelam Sharma-Walia
Journal:  Front Cell Infect Microbiol       Date:  2021-03-19       Impact factor: 5.293

4.  CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma.

Authors:  Long Liu; Zaoqu Liu; Jie Gao; Xudong Liu; Siyuan Weng; Chunguang Guo; Bowen Hu; Zhihui Wang; Jiakai Zhang; Jihua Shi; Wenzhi Guo; Shuijun Zhang
Journal:  Front Immunol       Date:  2022-07-27       Impact factor: 8.786

5.  BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.

Authors:  Maissa Mhibik; Erika M Gaglione; David Eik; Ellen K Kendall; Amy Blackburn; Keyvan Keyvanfar; Maria Joao Baptista; Inhye E Ahn; Clare Sun; Junpeng Qi; Christoph Rader; Adrian Wiestner
Journal:  Blood       Date:  2021-11-11       Impact factor: 22.113

Review 6.  KSHV: Immune Modulation and Immunotherapy.

Authors:  Grant Broussard; Blossom Damania
Journal:  Front Immunol       Date:  2020-02-07       Impact factor: 7.561

Review 7.  Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.

Authors:  Ming Yi; Xiaoli Zheng; Mengke Niu; Shuangli Zhu; Hong Ge; Kongming Wu
Journal:  Mol Cancer       Date:  2022-01-21       Impact factor: 27.401

8.  FCGBP Is a Prognostic Biomarker and Associated With Immune Infiltration in Glioma.

Authors:  Tengfeng Yan; Daofeng Tian; Junhui Chen; Yinqiu Tan; Yue Cheng; Liguo Ye; Gang Deng; Baohui Liu; Fanen Yuan; Shenqi Zhang; Linzhi Cai; Qianxue Chen
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.